Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: The importance of barrier repair therapy in patient management

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 626-631

  Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RETINOID DERIVATIVE;

ACNE VULGARIS; ARTICLE; BACTERIAL COLONIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; HUMAN; LIPID MEMBRANE; NONHUMAN; PATIENT CARE; SEBUM SECRETION; SKIN EXFOLIATION; SKIN FLORA; SKIN FUNCTION; SKIN PERMEABILITY; SKIN STRUCTURE; SKIN SURFACE; SKIN WATER LOSS; STAPHYLOCOCCUS; UNITED STATES; XEROSIS;

ACNE VULGARIS; ADMINISTRATION, ORAL; ANIMALS; DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; ISOTRETINOIN; SKIN; UNITED STATES;

EID: 84878632595     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663. (Pubitemid 46400177)
2. Layton A. The use of isotretinoin in acne. Dermatoendocrinology. 2009;1(3):162-169.
3. Cunliffe WJ, van de Kerkhof PCM, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194:351-357. (Pubitemid 27290560)
4. Layton A. Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol. 1992;27:S2-S7.
5. Ward A, Brogden RN, Heel RC, et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs. 1984;28:6-37. (Pubitemid 14112379)
6. Jones DH, King K, Miller AJ, et al. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol. 1983;108(3):333-343. (Pubitemid 13152551)
7. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490-496. (Pubitemid 14150139)
8. Layton AM, Knaggs H, Taylor J, et al. Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol. 1993;129(3):292-296. (Pubitemid 23284001)
9. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and diseased skin. J Clin Aesthet Dermatol. 2011;4(9):22-42.
10. Williams ML, Elias PM. Nature of skin fragility in patients receving retinoids for systemic effect. Arch Dermatol. 1981;117(10):611-619. (Pubitemid 11022587)
11. Elias PM. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol. 1986;15(4 Pt 2):797-809. (Pubitemid 17170784)
12. Elias PM, Fritsch PO, Lampev M, et al. Retinoid effects on epidermal structure, differentiation, and permeability. Lab Invest. 1981;44(6):531-540. (Pubitemid 11067583)
13. Herane MI, Fuenzalida H, Zegpi E, et al. Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase - a double-blind, randomized, placebo-controlled study. J Cosmet Dermatol. 2009;8(3):181-185.
14. Varani J, Burmeister B, Sitrin RG, at al. Expression of serine protease and metalloproteinases in organ-cultured human skin: altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion. Am J Pathol. 1994;145(3):561-573.
15. Nelson AM, Zhao W, Gilliland KL, at al, Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid -induced apoptosis of human sebaceous gland cells. J Clin Invest. 118(4):1468-1478.
16. Greene RS, Downing DT, Pochi PE, Strauss JS. Anatomical variation in the amount and composition of human skin surface lipid. J Invest Dermatol. 1970;54(3):240-7.
17. Melnik B, Kinner T, Plewig G. Influence of oral isotretinoin treatment on the composition of comedonal lipids: implications for comedogenesis in acne vulgaris. Arch Dermatol Res. 1988;280(2):97-102. (Pubitemid 18094685)
18. Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control iof skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol. 2005;153(6):1126-1136. (Pubitemid 41779566)
19. Başak PY, Cetin ES, Gürses I, Ozseven AG. The effects of systemic isotretinoin and antibiotic therapy on the microbial floras in patients with acne vulgaris. J Eur Acad Dermatol Venereol. 2012 Jan 13. doi: 10.1111/j.1468-3083.2011.04397.x. [Epub ahead of print]
20. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol. 1986;80(4):390-393. (Pubitemid 16050015)
21. Yamamato A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Derm Res. 1995;287:214-218.
22. Weber SU, Thiele JJ, Han N, Luu C, et al. Topical tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. Free Radical Biology & Medicine. 2003; 34: 170-176. (Pubitemid 36084321)
23. Tagami, H., Tadaki, T., Obata, M, at al. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guineapigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol. 1992;127, 470-475.
24. Stucker M, Hoffman M, Altmeyer P. Instrumental evaluation of retinoid-induced skin irritation. Skin Research and Technology. 2002; 8:133-40. (Pubitemid 34692973)
25. Draelos ZD; Ertel KD; Berge CE. Tretinoin facilitating facial retinization through barrier improvement. Cutis. 2006;78:275-281.
26. Del Rosso JQ. The role of the vehicle in combination acne therapy. Cutis. 2005;76(2 Suppl):15-8. (Pubitemid 41290889)
27. Del Rosso JQ. Moisturizers: function, formulation, and clinical applications. In: Draelos ZD, ed. Cosmeceuticals. Philadelphia, PA: Saunders Elsevier; 2009:97-102.
28. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771-788. (Pubitemid 37452637)
29. Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005;76(6 Suppl):7-12. (Pubitemid 43094508)
30. Del Rosso JQ. Understanding skin cleansers and moisturizers: the correlation of formulation science with the art of clinical use. Cosmetic Dermatology. 2003;16(11):19-31.
31. Johnson AW. Cosmeceuticals: function and the skin barrier. In: Draelos ZD, ed. Cosmeceuticals. Philadelphia, PA: Saunders-Elsevier; 2009:7-14.
32. Assessment of Dermatology Clinician Prescriber Habits when Treating Dry Skin. Market Research Study. SCS Healthcare Marketing, Mahwah, NJ 07430. September 2012.
33. Goodman G. Cleansing and moisturizing in acne patients. Am J Clin Dermatol. 2009;10 Suppl 1:1-6.
34. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17:26-34.
35. Lodén M.The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol. 2005;19(6):672-88. (Pubitemid 41743319)
36. Del Rosso JQ. Understanding skin cleansers and moisturizers: the correlation of formulation science with the art of clinical use. Cosmetic Dermatology. 2003;16(11):19-31.
37. Loden M. Effect of moisturizers on epidermal barrier function. Clinics in Dermatology. 2012;30:286-296.
38. Park KY, Kim DH, Jeong MS, et al. Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide- dominant emollient in patients with atopic dermatitis. J Korean Medical Sci. 2010;25(5):766-771.
39. Anderson PC, Dinulos JG. Are the new moisturizers more effective? Curr Opin Pediatr. 2009;21(4):486-490.
40. Lee YB, Park HJ, Kwon MJ, et al. Beneficial effects of pseudoceramidecontaining physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol. 2011;21(5):710-716.
41. Choi MJ, Maibach HI. Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol. 2005;6:215-223.
42. Mao-Qiang M, Brown BE,Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131:809-816.
43. Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17:49-56.
44. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198-208.
45. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324. (Pubitemid 27332923)
46. Hanifin JM, Hebert AA, Mays SR, et al. Effects of a low-potency corticosteroid formulation plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res. 1998;59:227-233. (Pubitemid 28206661)
47. Boguniewicz M. Conventional topical treatment of atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York, NY: Marcel Dekker;2002:453-477.
48. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis. 2008;81:87-91.
49. Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol. 1997;37:403-408. (Pubitemid 27430637)
50. Ananthapadmanabhan KP, Moore DJ, Subramanyan K, Misra M, Meyer F. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther. 2004;17:16-25.
51. Ananthapadmanabhan KP, Yang L, Vincent C, et al. A new technology in mild and moisturizing cleansing liquids. Cosmet Dermatol. 2009;22:307-316.
52. Elias PM. Physiologic lipids for barrier repair in dermatology. In: Draelos ZD, ed. Cosmeceuticals. 1st ed. Philadelphia, PA: Elsevier-Saunders; 2005:63-70.